The University of Weston Australia, to be more specific University Department of Medicine and Australian Neuromuscular Research Institute, Queen Elizabeth II Medical Center, Nedlands, Australia has developed a study regarding malignant mesothelioma cancer, using murine models of this malignancy that resembled at that time with the humane disease and they have shown that immunotherapy may represent an effective antitumor response. This is a great step in malignant mesothelioma cancer treatments.
Malignant mesothelioma cancer
Malignant mesothelioma is a type of cancer, a rare type, but present in the United States, caused by exposure to asbestos. Inhaling or swallowing asbestos fibers leads to serious injuries to the lung and it can affect other internal organs to.
Malignant mesothelioma cancer is represented by a solid tumor located in the pleural area and is called pleural mesothelioma, it can affect also the abdominal cavity, this type of mesothelioma is called peritoneal mesothelioma.
Study on murine antitumor response
The study elaborated by University of Western Australia, was related to the effects of the rIL, on murine antitumor immune response, using a nonimmunogenic murine MM tumor cell line (AB1) in vivo. Using this elements and specific methods the team at the University of Weston established that effective immune responses are real on long term.
The rIL 12 induced effects were dependent on the involvement of both CD4+ and CD8+ but not natural killer (NK) cells.
Effective inhibition of tumor growth also occurred, when rIL 12 was released within MM tumor by co-administration of MM cells that have been stably transferred with the gene of rIL 12.
Results studies are amazing- rIL 12 is an effective antitumor response, and is an important factor in immunotherapy of malignant mesothelioma.